The overall goal of this proposal is to acquire funds to purchase a triple quadrupole mass spectrometer to replace an existing 9-year old Waters Micromass Quattro LC instrument. The funds will be used to purchase a Applied Biosystems (AB) SCIEX Triple QuadTM 5500 (API 5500) system (a tandem quadrupole mass spectrometer) coupled with an ACQUITY UPLCTM chromatographic system that will be dedicated to support NIH-funded investigators requiring sensitive quantitative analysis. A group of 9 investigators at the Johns Hopkins Medical Institutions (4 major, 5 minor) has been identified whose research (100% NIH-funded) is dependent on analyses which are only possible with the requested instrument. The Johns Hopkins University Kimmel Cancer Center (JHU KCC) is a NCI-Designated Comprehensive Cancer Center since 1976 and is part of the Johns Hopkins Medical Institute which has the Institute for Clinical and Translational Research (ICTR) Award. The JHU KCC Analytical Pharmacology Core (JHU KCC APC) is a Cancer Center shared resource that provides funded investigators with technical expertise and access to large equipment for quantitative analysis of anticancer drugs and related compounds. The ICTR has broadened access to the JHU KCC APC to non-Cancer Center members, The JHU KCC APC is used heavily by NIH-funded grants supporting both Phase I trials (U01),and preclinical research projects (e.g., preclinical development of thapsigargin prodrugs (R01), agents in Caseating Granulomas (R01), and agents in Buruli ulcers (R01)). As the JHU KCC APC supports both early clinical development of anti-cancer drugs and pre-clinical cancer-related research, it is a critical resource for the Cancer Center and the Johns Hopkins Medical Institutions. This critical resource has experienced a rapid growth in the number of basic and clinical investigators requiring analytical services. As a result, usage of the existing LC/MS/MS instrument is currently at full capacity. As Waters Corporation is terminating the Micromass Quattro LC product line, by ceasing to provide service contracts and replacement parts for this instrument in late 2009, the capacity of the JHU KCC APC will decrease substantially (50%) unless a qualified new mass spectrometer is functionally up and running in our laboratory prior to the Micromass Quattro LC being fully decommissioned. The addition of a new LC/MS/MS to replace the outdated LC/MS/MS will directly benefit NIH grant-funded early clinical and preclinical trial projects. In addition, it will indirectly benefit NIH-funded contracts and studies that are not currently NIH funded by freeing time on the existing LC/MS/MS. The LC/MS/MS capability of the JHU KCC APC will contribute to the long-range biomedical research goals of the Johns Hopkins Medical Institutions.

Public Health Relevance

The ability to quantify drugs and their metabolites in cells, plasma, and tissues with high sensitivity and selectivity is an essential need of research projects that aim to improve the therapy of diseases or to understand the basic mechanisms of biological processes. The proposed updated analytical instrument will bring the state-of-the-art instrumentation necessary to the Johns Hopkins Medical Institutions, thereby advancing many projects that seek to improve the therapy of serious diseases such as cancer and tuberculosis.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Biomedical Research Support Shared Instrumentation Grants (S10)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BCMB-R (30))
Program Officer
Birken, Steven
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Fox, Jennifer M; Moynihan, James R; Mott, Bryan T et al. (2016) Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs. Oncotarget 7:7268-79
Anders, Nicole M; Liu, Jianyong; Wanjiku, Teresia et al. (2016) Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci 1022:38-45
Çelik, Haydar; Bulut, Gülay; Han, Jenny et al. (2016) Ezrin Inhibition Up-regulates Stress Response Gene Expression. J Biol Chem 291:13257-70
Jackson, Sadhana; Anders, Nicole M; Mangraviti, Antonella et al. (2016) The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol 126:433-9
Anders, Nicole M; Wanjiku, Teresia M; He, Ping et al. (2016) A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine. Biomed Chromatogr 30:494-6
Jin, Jing; Gu, Hao; Anders, Nicole M et al. (2016) Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. Neuromolecular Med 18:581-592
Bol, Guus M; Vesuna, Farhad; Xie, Min et al. (2015) Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med 7:648-69
Wicks, Robert T; Azadi, Javad; Mangraviti, Antonella et al. (2015) Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. Neuro Oncol 17:70-80
Paniello, Randal C; Park, Andrea (2015) Effect on laryngeal adductor function of vincristine block of posterior cricoarytenoid muscle 3 to 5 months after recurrent laryngeal nerve injury. Ann Otol Rhinol Laryngol 124:484-9

Showing the most recent 10 out of 37 publications